Skip to main content
Sign In

Jonathan Gutman, MD

Jonathan Gutman, MD
Jonathan Gutman, MD
University of Colorado School of Medicine
  • Clinical Director of Allogeneic Stem Cell Transplantation
  • Co-Medical Director, University of Colorado Cord Blood Bank
  • Laboratory Medical Director, University of Colorado Clinical Stem Cell Laboratory
  • Associate Professor of Medicine
Contact information

Anschutz Medical Campus
1665 Aurora Court, MS F754
Aurora, CO  80045


​Dr. Gutman received his BA in history from Princeton University.  He completed medical school at New York University, residency at the University of Colorado, and fellowship at the Fred Hutchinson Cancer Research Center.  He returned to the University of Colorado in 2009.  He serves as the director of allogeneic stem cell transplantation, co-medical director of the University of Colorado Cord Blood Bank, laboratory medical director of the clinical stem cell laboratory, and chairman of the University of Colorado Cancer Center Protocol Review and Monitoring system.  His research focuses on optimization of allogeneic transplantation and immunotherapy with a particular emphasis on cord blood transplantation.  He is an ad hoc reviewer for numerous journals and is the principal investigator on numerous clinical trials.  In addition he serves on several national committees related to improving stem cell transplantation.
  • Princeton University, BA, 1996
  • New York University School of Medicine, MD, 2002
  • University of Colorado, Residency, 2005
  • Fred Hutchinson Cancer Research Center/University of Washington, Fellowship, 2008
​I am a clinical/translational researcher focused on blood cancers and stem cell transplantation.  In the clinic, I conduct trials designed to improve outcomes following allogeneic stem cell transplantation with an emphasis on reducing relapse risk and decreasing toxicities associated with transplantation.  I have a particular focus on optimizing cord blood transplantation.  In the laboratory, my primary interests are transplant immunology and immunotherapy.  We conduct translational studies designed to better understand immune reconstitution following transplantation and develop novel strategies to use the immune system to improve outcomes.
1. GyurkoczaB, Gutman J, Nemecek ER, Bar M, Milano F, Ramakrishnan A, Scott B, Fang M, Wood B, Pagel JM, Baumgart J, Delaney C, Maziarz RT, Sandmaier BM, Estey EH, Appelbaum FR, Storer BE, Deeg HJ.  Treosulfan, Fludarabine and 2 Gy Total Body Irradiation Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with MDS and AML.  Biology of Blood and Marrow Transplant. 2014;20:549-55
2. Marty FM, Winston DJ, Rowley SD, Vance E, Papanicolaou GA, Mullane KM, Brundage TM, Robertson AT, Godkin S, Momméja-Marin H, Boeckh M; CMX001-201 Clinical Study Group. (Gutman J 10/26) CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med. 2013;369:1227-36.
3. Narayanan V, Gutman JA, Pollyea DA, Jimeno A.  Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.  Drugs of Today. 2013;49:447-56.
4. Coffey DG, Pollyea DA, Myint H, Smith C, Gutman JA. Adjusting DLCO for hemoglobin and its effects on the Hematopoietic Cell Transplantation-specific Comorbidity Index. Bone Marrow Transplantation 2013;48:1253-6.
5. Narayanan V, Pollyea DA, Gutman JA, Jimeno A.  Ponatinib for the treatment of Ph+ALL and CML.  Drugs of Today. 2013;49:261-9.
6. Ostronoff F, Milano F, Gooley T, Gutman JA, McSweeney P, Petersen F, Sandmaier BM, Storb R, Delaney C. Umbilical cord blood transplantation in patients with hematological malignancies using a non-ATG containing reduced intensity preparative regimen. Bone Marrow Transplantation 2013;48:782-786.
7. Petz L, Redei I, Bryson Y, Regan D, Kurtzberg J, Shpall E, Gutman J, Querol S, Clark P, Bravo A, Tonai R, Santos S, Spellman S, Gragert L, Boo M, Rossi J, Li S, Li H, Senitzer D, Rosenthal J, Zaia J, Forman S, Chow R. Hematopoietic cell transplantation with cord blood for cure of HIV infections. Biology of Blood and Marrow Transplant 2013;19:393-397.
8. Gutman JA, Hoffner B. A novel CEBPA germline variant in a case of acute myeloid leukemia.  Leukemia and Lymphoma 2012;53:1006-7.
9. Milano F, Chien JW, Riffkin I, Gutman JA, Newell L, Pergam SA, Delaney C. Stable long-term pulmonary function after myeloablative double cord blood transplant.  Biology of Blood and Marrow Transplant 2012;18:309-13.Milano F, Pergam SA, Xie H, Leisenring WM, Gutman JA, Riffkin I, Chow V, Boeckh MJ, Delaney C.  Intensive strategy to prevent cytomegalovirus disease in seropositive umbilical cord blood transplant recipients.  Blood 2011;118:5689-96.
10. Gutman JA, Miller S, Kuenne S, Oppenheim J, Stark C, Zarlengo G, Quinones R, Freed BM.  Cord blood collection after cesarean section improves banking efficiency. Transfusion 2011;51:2050-1.
11. Brunstein CG, Gutman JA, Defor TE, Gooley T, Verneris MR, Woolfrey A, Weisdorf DJ, Appelbaum FR, Wagner JE, Delaney C.  Allogeneic hematopoietic cell transplantation for hematological malignancy: relative risks and benefits of double umbilical cord blood.  Blood 2010;116;4693-9.
12. Gutman JA, Turtle CJ, Manley TJ, Heimfeld S, Bernstein IR, Riddell SR, and Delaney C.  Single unit dominance following double unit umbilical cord blood transplantation coincides with a specific CD8+ T cell response against the non-engrafted unit. (Plenary paper) Blood 2010;115:757-65.
13. Delaney C, Gutman JA, and Appelbaum FR.  Cord blood transplantation for hematologic malignancies: conditioning regimens, double cord transplant, and infectious complications.  British Journal of Haematology, 2009;147:207-16.
14. Gutman JA, Leisenring W, Appelbaum FR, Woolfrey AE, Delaney C.  Low relapse without excessive transplant related mortality following myeloablative cord blood transplantation for acute leukemia in complete remission: a matched cohort analysis. Biology of Blood and Marrow Transplant 2009;15:1122-9.
15. Fagenholz PJ, Gutman JA, Murray AF, Noble VE, Camargo CA, Harris NS.  Optic nerve sheath diameter correlates with the presence and severity of acute mountain sickness: evidence for increased intracranial pressure.  Journal Applied Physiology 2009;106:1207-11.
16. Gutman JA, McKinney SK, Warnock SL, Smith AG, Woolfrey AE, Hansen JA, and Delaney C.  Prospective monitoring for alloimmunization in cord blood transplantation: “virtual crossmatch” can be used to demonstrate donor-directed antibodies.  Transplantation 2009;87:415-8.
17. Gutman JA, Allen CT, Madtes DK, Schramm J, Delaney C.  Pulmonary veno-occlusive disease following reduced-intensity cord blood transplantation.  Bone Marrow Transplant 2008;42:559-61.
18. Fagenholz PJ, Gutman JA, Murray AF, Noble VE, Camargo CA, Harris NS.  Evidence for increased intracranial pressure in high altitude pulmonary edema.  High Altitude Medicine and Biology 2007;8:331-336.   
19. Fagenholz PJ, Gutman JA, Murray AF, Noble VE, Wu A, Ziemer G, Harris NS.  Arterial thrombosis at high altitude resulting in loss of limb.  High Altitude Medicine and Biology 2007;8:340-347.
20. Fagenholz PJ, Murray AF, Gutman JA, Findley J, Harris NS.  New onset anxiety disorders at high altitude.  Wilderness and Environmental Medicine 2007;18:312-316.
21. Gutman JA, Peck AJ, Kuypers J, Boeckh M.  Rhinovirus as a cause of fatal lower respiratory tract infection in adult stem cell transplantation patients: a report of two cases.  Bone Marrow Transplant 2007;40:809-811.
22. Fagenholz PJ, Gutman JA, Murray AF, Harris NS.  Treatment of high altitude pulmonary edema at 4240m in Nepal. High Altitude Medicine and Biology 2007;8:139-146.
23. Fagenholz PJ, Gutman JA, Murray AF, Noble VE, Thomas SH, Harris NS.  Chest ultrasonography for the diagnosis and monitoring of high altitude pulmonary edema.  Chest 2007;131:1013-1018.
24. Gutman JA, Shpall EJ, Nieto Y, McSweeney P, McNiece I. Long-term follow up of breast cancer patients transplanted with autologous ex vivo expanded peripheral blood progenitor cells. Cell Preservation Technology 2006; 4: 4-8.
25. Gutman JA, Bearman S, Nieto Y, Sweetenham JW, Jones RB, Shpall EJ, Zheng C, Baron A, McSweeney P.  Autologous transplantation followed closely by reduced-intensity allogeneic transplantation as consolidative immunotherapy in advanced lymphoma: a feasibility study.  Bone Marrow Transplantation  2005; 36: 443-451.
26. Olson AL, Gutman JA, Welsh C.  A fifty year old male with skin lesions and multiple pulmonary nodules. Chest 2004;125:2322-2327.